Vera Therapeutics Valuation
| VERA Stock | USD 27.08 0.62 2.24% |
At this time, the company appears to be overvalued. Vera Therapeutics has a current Real Value of $26.4 per share. The regular price of the company is $27.08. Our model measures the value of Vera Therapeutics from inspecting the company fundamentals such as Shares Owned By Institutions of 92.91 %, return on equity of -0.45, and Shares Outstanding of 63.75 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Vera Therapeutics' valuation include:
Overvalued
Today
Please note that Vera Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Vera Therapeutics is based on 3 months time horizon. Increasing Vera Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Vera Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vera Stock. However, Vera Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 27.08 | Real 26.4 | Target 64.58 | Hype 27.7 | Naive 29.76 |
The real value of Vera Stock, also known as its intrinsic value, is the underlying worth of Vera Therapeutics Company, which is reflected in its stock price. It is based on Vera Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Vera Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Vera Therapeutics helps investors to forecast how Vera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vera Therapeutics more accurately as focusing exclusively on Vera Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Vera Therapeutics' intrinsic value based on its ongoing forecasts of Vera Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Vera Therapeutics' closest peers. If more than one evaluation category is relevant for Vera Therapeutics we suggest using both methods to arrive at a better estimate.
Vera Therapeutics Cash |
|
Vera Valuation Trend
Comparing Vera Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Vera Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Vera Therapeutics Total Value Analysis
Vera Therapeutics is at this time projected to have valuation of 1.18 B with market capitalization of 1.77 B, debt of 54.64 M, and cash on hands of 131.93 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Vera Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.18 B | 1.77 B | 54.64 M | 131.93 M |
Vera Therapeutics Asset Utilization
One of the ways to look at asset utilization of Vera is to check how much profit was generated for every dollar of assets it reports. Vera Therapeutics has a negative utilization of assets of -0.25 %, losing $0.002514 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Vera Therapeutics shows how discouraging it operates for each dollar spent on its assets.Vera Therapeutics Ownership Allocation
The majority of Vera Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vera Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vera Therapeutics. Please pay attention to any change in the institutional holdings of Vera Therapeutics as this could imply that something significant has changed or is about to change at the company.Vera Therapeutics Profitability Analysis
Net Loss for the year was (152.15 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Vera Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Vera Therapeutics and how it compares across the competition.
About Vera Therapeutics Valuation
The stock valuation mechanism determines Vera Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Vera Therapeutics. We calculate exposure to Vera Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vera Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.1 M | 2.2 M | |
| Pretax Profit Margin | (46.40) | (48.72) | |
| Operating Profit Margin | (49.31) | (51.77) | |
| Net Loss | (46.40) | (48.72) |
Vera Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 55.3 M |
Vera Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Vera Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Vera we look at many different elements of the entity such as Vera's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Vera Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Vera Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Vera Therapeutics' worth.Complementary Tools for Vera Stock analysis
When running Vera Therapeutics' price analysis, check to measure Vera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vera Therapeutics is operating at the current time. Most of Vera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vera Therapeutics' price. Additionally, you may evaluate how the addition of Vera Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |